tanezumab
mAbexperimental
Tanezumab is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006. — Wikipedia
Clinical trial activity
38 trials · 51 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
35
Phase 3
20
Phase 4
0
Earliest trial started Mar 1, 2006 (NCT00394563)
Timeline
Indications
Studied for
- Arthritis · Phase 3
- Back Pain · Phase 1
- Cancer Pain · Phase 3
- Chronic Pain · Phase 3
- Cystitis, Interstitial · Phase 2
- Diabetes Mellitus · Phase 2
- Endometriosis · Phase 2
- Healthy Volunteers · Phase 1
- Low Back Pain · Phase 3
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 2
- Neuralgia, Postherpetic · Phase 2
- Osteoarthritis · Phase 3
- Osteoarthritis, Hip · Phase 3
- Osteoarthritis, Knee · Phase 3
- Pain · Phase 3
- Palliative Care · Phase 2
- Pancreatitis, Chronic · Phase 2
- Prostatitis · Phase 2
- Schwann Cells · Phase 2
Mechanism of action
- Beta-nerve growth factorINHIBITOR
NGF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTanezumab ↗
- ChEMBLCHEMBL2108567 ↗
Also known as
- anti-ngf ab
- pf04383119
- pf 04383119
- pf-04383119
- pf-04383119
- pf-04383119
- pf4383119
- pf 4383119
- pf-4383119
- pf-4383119
- ri 624
- ri-624
- ri624 mab
- rn624
- rn624
- rn 624
- rn-624
- rn624 mab
- tanezumab
- tanezumab
- tanezumab
- tanezumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04163419 | Phase 2 | Feb 29, 2020 | Harvard University, Pfizer |
| NCT03031938 | Phase 3 | Oct 31, 2017 | Eli Lilly, Pfizer |
| NCT02725411 | Phase 3 | May 26, 2016 | Pfizer |
| NCT02709486 | Phase 3 | Mar 2, 2016 | Eli Lilly, Pfizer |
| NCT02697773 | Phase 3 | Jan 21, 2016 | Pfizer |
| NCT02609828 | Phase 3 | Oct 28, 2015 | Albert Einstein Israelite Hospital, Ambulancia Klinickej onkologie FNsP Nove Zamky, Bajcsy-Zsilinszky Hospital, Ballarat Health Services, Biovirtus, Complexo Hospitalario Universitario de A Coruña, Departmental Hosptital of Vendee, Eli Lilly, Faculdade de Medicina do ABC, Flinders University, Fundacao Antonio Prudente, Fundacion Favaloro Para La Docencia e Investigacion Medica, Hallym University, Hetenyi G Korhaz, Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w Gdansku, Hospital de Cancer de Barretos - Fundacao Pio XII, Hospital Sanitas La Moraleja, Hospital Universitario Fundación Alcorcón, Instituto de Oncologia de Rosario, Instituto do Cancer do Estado de São Paulo, Keimyung University, Klinikum Klagenfurt, L'Hospitalet de Llobregat, Masarykuv onkologicky ustav, Klinika komplexni onkologicke pece, Monash University, National Institutes of Health (NIH), Nemocnice Horovice, Niepliczny Zakad Opieki Zdrowotnej Zespo Medyczno-Opieku-Czy Alicja Kluczna, Nishinomiya Municipal Central Hospital, Nuhr Medical Center, Oncocenter Onclogie Clinica S.R.L, Oncolab SRL, Oncology department of Nemocnice Benesov, Pfizer, Polyclinique de L'ormeau, Poradnia Medycyny Paliatywnej Hospicjum Palium, Powiatowy Zespo Zakadow Opieki Zdrowotnej w Bdzinie, Oddzia Opieki Paliatywnej Szpital Czelad, Sanera, s.r.o., Seoul National University, Slovak Research Center, Stowarzyszenie Przyjacio Chorych Hospicjum, Sue Ryder Home, Sungkyunkwan University, The National Cancer Center, Universidad Autonoma de Madrid, University Alicante, University of Edinburgh, Velindre NHS Trust, Wilhelminenspital der Stadt Wien, Yonsei University |
| NCT02528253 | Phase 3 | Aug 18, 2015 | Eli Lilly, Pfizer |
| NCT02528188 | Phase 3 | Jul 21, 2015 | Pfizer |
| NCT01146561 | Phase 2 | Oct 1, 2010 | Pfizer |
| NCT01127893 | Phase 3 | Jun 1, 2010 | Pfizer |
| NCT01089725 | Phase 3 | Mar 1, 2010 | Pfizer |
| NCT01087203 | Phase 2 | Mar 1, 2010 | Pfizer |
| NCT00960804 | Phase 3 | Feb 1, 2010 | Pfizer |
| NCT00999518 | Phase 2 | Jan 1, 2010 | Pfizer |
| NCT01030640 | Phase 1 | Dec 1, 2009 | Pfizer |
| NCT00994890 | Phase 2 | Nov 1, 2009 | Pfizer |
| NCT00830180 | Phase 2 | Oct 1, 2009 | Pfizer |
| NCT00985621 | Phase 3 | Oct 1, 2009 | Pfizer |
| NCT00864097 | Phase 3 | Aug 1, 2009 | Pfizer |
| NCT00924664 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2009 | Pfizer |
Showing 20 of 38 trials
Page 1 / 2
Organizations
Research & Development (51)
51 organizations
Page 1 / 3